Passage BIO (PASG) Free Cash Flow (2019 - 2026)
Passage BIO (PASG) posted quarterly Free Cash Flow of -$13.0 million for Q1 2026, up 6.21% year-over-year from -$12.2 million in Q1 2025, and down 100.45% quarter-over-quarter from -$6.5 million in Q4 2025.
Passage BIO (PASG) Free Cash Flow (2019 - 2026) Analysis & Trends
Passage BIO's Free Cash Flow history runs 8 years deep, the most recent figure standing at -$13.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 6.21% year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at -$30.6 million (up 28.54% YoY), while the FY2025 annual figure was -$31.5 million, up 34.34% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$13.0 million, down from -$6.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$4.9 million in Q3 2025, with the low at -$45.4 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$17.2 million (2023), against an average of -$17.1 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 44.15% in 2022, then soared 61.15% in 2024.
- Passage BIO's Free Cash Flow stood at -$24.5 million in 2022, then increased by 20.27% to -$19.5 million in 2023, then soared by 56.69% to -$8.5 million in 2024, then rose by 23.4% to -$6.5 million in 2025, then plunged by 100.45% to -$13.0 million in 2026.
- Business Quant data shows PASG's Free Cash Flow at -$13.0 million in Q1 2026, -$6.5 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | -9.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.18 Mn |
| Jun 30, 2026 | -9.18 Mn |
| Mar 31, 2026 | -12.99 Mn |
| Mar 31, 2026 | -12.99 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -8.46 Mn |
| Dec 31, 2024 | -8.46 Mn |
| Sep 30, 2024 | -7.45 Mn |
| Sep 30, 2024 | -7.45 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Mar 31, 2024 | -18.93 Mn |
| Mar 31, 2024 | -18.93 Mn |